Author: Ben Burton (United Kingdom)
Co-authors: Maurizio Parodi, Ignasi Jurgens, Xavier Zanlonghi, Dan Hornan, Johann Roider, Katrin Lorenz
Purpose
Dry Age-related macular degeneration (AMD) is a leading contributor to vision loss and blindness in adults over 65. There is a growing body of evidence to support Photobiomodulation (PBM) in the 500-1000 nm wavelength spectrum, as a novel treatment for dry AMD. PBM uses wavelengths of light to target cytochrome c oxidase of the mitochondrial respiratory chain to activate energy production and improve metabolic outputs. PBM improves cellular activities which positively impacts on anatomical and clinical endpoints. The Valeda® Light Delivery System is CE marked in the EU and was utilized to evaluate the safety and efficacy of PBM in dry AMD subjects.
Setting/Venue
The LIGHTSITE II multi-center trial was a prospective, double masked, randomized study conducted at eight clinical sites across 5 countries throughout Europe (United Kingdom, Germany, France, Spain, Italy).
Methods
The LIGHTSITE II study enrolled 44 dry AMD subjects (53 eyes). The LIGHTSITE study enrollment was truncated due to COVID-19 (Targeted 96 subjects and 144 eyes) but extended the positive findings of LIGHTSITE I by treating earlier, intermediate dry AMD subjects with 3 rounds of PBM treatments. The subjects had 20/32 to 20/100 vision impairment and no central (1 mm) Geographic Atrophy (GA) involvement. Subjects were randomized (2:1) and received either PBM or sham treatment with the marketed Valeda® Light Delivery System delivered 3x per week over 3-4 weeks (9 treatments total per series) with repeated treatments at baseline (BL), 4, and 8 months. Valeda uses a multiwavelength treatment comprised of 590 nm, 660 nm and 850 nm wavelengths applied to the subject’s eyes for a total of 4-5 minutes per treatment per eye. Due to the COVID-19 interruption, a further analysis was conducted in patients that completed all 3 rounds of treatments as per protocol.
Results
Subjects were 100% Caucasian and included 17 Males (38.6%) and 27 Females (61.4%). The subject’s mean age was 74.1 years and time since dry AMD diagnosis was 3.7 years. PBM-treated eyes showed statistically significant improvement in BCVA change from BL at 9-months in the modified ITT group (n = 51 eyes, p = 0.02). Subjects showed sustained vision improvement in BCVA at 9-months from baseline (p = 0.01) with approximately a 4-letter gain improvement in the PBM-treated group versus a 0.5 letter gain in the sham-treated group (p = 0.1) for patients that received all 27 PBM treatments (29 eyes). 35.3% of PBM-treated eyes showed 5 letters improvement at 9 months. Conversion from dry to wet AMD was 3.1% for PBM, 5.6% in sham and 4.8% in non-study eyes. Eyes considered high-risk for conversion to wet AMD (36.3%)(i.e., other eye had exudative macular neovascularization) showed a 0% rate of conversion following PBM. No significant drusen growth was observed at 9 months in PBM-treated compared to the sham group who showed significant drusen growth over time. A 44% decrease in geographic atrophy growth following PBM was observed at 9-months. No safety concerns or signs of phototoxicity were noted related to PBM.
Conlusions
The LIGHTSITE II study investigated PBM in intermediate Dry AMD eyes on both anatomical and clinical outcomes in a double masked, randomized, sham-controlled design. Statistically significant improvements in BCVA were observed at 9 months from baseline in the PBM-treated subjects. PBM retreatment with 4 months intervals provided consistent improvements in visual function and in morphological signs of dry AMD disease activity and maintenance of clinical outcome benefits. Dry AMD patients treated with PBM demonstrated both functional and anatomical improvements following PBM treatments. PBM-treated patients showed no significant drusen growth and reductions in geographic atrophy growth suggesting potential disease-modifying effects. The anatomical benefits will require larger clinical trials to confirm benefits. No device related serious adverse effects were seen in the study. PBM therapy represents an early and cost-effective, non-invasive treatment for dry AMD patients. These results confirm previous clinical testing of PBM and support its use as a novel treatment for dry AMD patients.
Financial Disclosure
Not applicable
Comments
-